Cisplatin Treatment Options

A collection of 1422 research studies where Cisplatin is the interventional treatment. These studies are located in the United States. Cisplatin is used for conditions such as Head and Neck Cancer, Lung Cancer and Non-small Cell Lung Cancer.

Home

All Treatments

Cisplatin

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Trial

Evaluating an Investigational Treatment for Hidradenitis Suppurativa

Recruiting

The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.

Conditions:

All Conditions

Hidradenitis suppurativa (Skin disorder)

Dermatology

Learn More

Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

NCT00304070

Completed

This phase III clinical trial is studying how well cisplatin-based chemotherapy and/or surgery works in treating young patients with stage I, stage II, stage III or stage IV adrenocortical cancer. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving chemotherapy before surgery may make the tumor s... Read More

Gender:

ALL

Ages:

21 years and below

Trial Updated:

02/26/2024

Locations: Children's Hospital of Alabama, Birmingham, Alabama +90 locations

Children's Hospital of Alabama, Birmingham, Alabama

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

Banner University Medical Center - Tucson, Tucson, Arizona

University of Arkansas for Medical Sciences, Little Rock, Arkansas

Kaiser Permanente Downey Medical Center, Downey, California

Miller Children's and Women's Hospital Long Beach, Long Beach, California

Children's Hospital Los Angeles, Los Angeles, California

Valley Children's Hospital, Madera, California

Children's Hospital of Orange County, Orange, California

Lucile Packard Children's Hospital Stanford University, Palo Alto, California

Children's Hospital Colorado, Aurora, Colorado

Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado

University of Connecticut, Farmington, Connecticut

Connecticut Children's Medical Center, Hartford, Connecticut

Alfred I duPont Hospital for Children, Wilmington, Delaware

Children's National Medical Center, Washington, District of Columbia

Lee Memorial Health System, Fort Myers, Florida

Nemours Children's Clinic-Jacksonville, Jacksonville, Florida

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida

Nemours Children's Clinic - Orlando, Orlando, Florida

Nemours Children's Clinic - Pensacola, Pensacola, Florida

Sacred Heart Hospital, Pensacola, Florida

Johns Hopkins All Children's Hospital, Saint Petersburg, Florida

Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida

Saint Mary's Hospital, West Palm Beach, Florida

Tripler Army Medical Center, Honolulu, Hawaii

Lurie Children's Hospital-Chicago, Chicago, Illinois

University of Chicago Comprehensive Cancer Center, Chicago, Illinois

Saint Jude Midwest Affiliate, Peoria, Illinois

Southern Illinois University School of Medicine, Springfield, Illinois

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

Riley Hospital for Children, Indianapolis, Indiana

University of Kentucky/Markey Cancer Center, Lexington, Kentucky

Norton Children's Hospital, Louisville, Kentucky

Tulane University Health Sciences Center, New Orleans, Louisiana

Sinai Hospital of Baltimore, Baltimore, Maryland

Walter Reed National Military Medical Center, Bethesda, Maryland

Dana-Farber Cancer Institute, Boston, Massachusetts

Wayne State University/Karmanos Cancer Institute, Detroit, Michigan

Michigan State University Clinical Center, East Lansing, Michigan

University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota

Children's Mercy Hospitals and Clinics, Kansas City, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada

Nevada Cancer Research Foundation NCORP, Las Vegas, Nevada

Hackensack University Medical Center, Hackensack, New Jersey

Morristown Medical Center, Morristown, New Jersey

Newark Beth Israel Medical Center, Newark, New Jersey

Overlook Hospital, Summit, New Jersey

Albany Medical Center, Albany, New York

University of Rochester, Rochester, New York

New York Medical College, Valhalla, New York

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Duke University Medical Center, Durham, North Carolina

Children's Hospital Medical Center of Akron, Akron, Ohio

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Rainbow Babies and Childrens Hospital, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Nationwide Children's Hospital, Columbus, Ohio

Dayton Children's Hospital, Dayton, Ohio

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Geisinger Medical Center, Danville, Pennsylvania

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania

Prisma Health Richland Hospital, Columbia, South Carolina

BI-LO Charities Children's Cancer Center, Greenville, South Carolina

Greenville Cancer Treatment Center, Greenville, South Carolina

Saint Jude Children's Research Hospital, Memphis, Tennessee

Driscoll Children's Hospital, Corpus Christi, Texas

UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas

Cook Children's Medical Center, Fort Worth, Texas

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas

Methodist Children's Hospital of South Texas, San Antonio, Texas

University of Texas Health Science Center at San Antonio, San Antonio, Texas

Primary Children's Hospital, Salt Lake City, Utah

University of Vermont and State Agricultural College, Burlington, Vermont

University of Virginia Cancer Center, Charlottesville, Virginia

Children's Hospital of The King's Daughters, Norfolk, Virginia

Seattle Children's Hospital, Seattle, Washington

West Virginia University Charleston Division, Charleston, West Virginia

Children's Hospital of Wisconsin, Milwaukee, Wisconsin

Princess Margaret Hospital for Children, Perth, Western Australia

Boldrini Children's Cancer Center, Campinas, San Paulo

Instituto De Oncologia Pediatrica, Sao Paulo, Not set

Alberta Children's Hospital, Calgary, Alberta

British Columbia Children's Hospital, Vancouver, British Columbia

IWK Health Centre, Halifax, Nova Scotia

McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario

Hospital for Sick Children, Toronto, Ontario

Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec

Centre Hospitalier Universitaire de Quebec, Quebec, Not set

Conditions: Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7, Stage III Adrenal Cortical Carcinoma AJCC v7, Stage IV Adrenal Cortical Carcinoma AJCC v7

Learn More ›

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT05500092

Recruiting

An open label, randomized study of neoadjuvant nivolumab and chemotherapy, with or without sub-ablative stereotactic body radiation therapy, for resectable stage IIA to IIIB non-small cell lung cancer

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/13/2024

Locations: Montefiore Medical Center-Albert Einstein College of Medicine, Bronx, New York

Conditions: Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Learn More ›

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

NCT02422498

Completed

The study is being done to find out if the results of a pre-treatment biopsy can predict response to cisplatin and radiation treatment for patients with metastatic or recurrent triple negative breast cancer.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

02/05/2024

Locations: Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey +6 locations

Conditions: Locally Recurrent/Metastatic Triple Negative Breast Cancer

Learn More ›

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

NCT03661320

Active Not Recruiting

The purpose of this study is to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer (MIBC).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/29/2024

Locations: Local Institution - 0022, Tucson, Arizona +171 locations

Local Institution - 0022, Tucson, Arizona

UC Davis Comprehensive Cancer Center, Sacramento, California

Local Institution - 0021, Littleton, Colorado

Local Institution - 0036, Pensacola, Florida

Local Institution - 0004, Tampa, Florida

Local Institution - 0144, Atlanta, Georgia

Local Institution - 0005, Chicago, Illinois

Local Institution - 0006, Peoria, Illinois

Local Institution - 0181, Columbia, Maryland

Local Institution - 0009, Boston, Massachusetts

Local Institution - 0166, Boston, Massachusetts

Local Institution - 0209, Boston, Massachusetts

Local Institution - 0025, Minneapolis, Minnesota

Local Institution - 0129, Minneapolis, Minnesota

Local Institution - 0183, Omaha, Nebraska

Local Institution - 0001, Omaha, Nebraska

Local Institution - 0024, Las Vegas, Nevada

Local Institution - 0029, Albany, New York

Local Institution - 0069, Lake Success, New York

Local Institution - 0047, New York, New York

Local Institution - 0191, Cleveland, Ohio

Local Institution - 0028, Tigard, Oregon

Local Institution - 0189, Charleston, South Carolina

Local Institution - 0007, Nashville, Tennessee

Local Institution - 0030, Austin, Texas

Local Institution - 0023, Norfolk, Virginia

Local Institution - 0051, Capital Federal, Buenos Aires

Local Institution - 0049, Ciudad Autónoma de Buenos Aires, Buenos Aires

Local Institution - 0151, Ciudad Autonoma Buenos Aires, Distrito Federal

Local Institution - 0131, Garran, Australian Capital Territory

Local Institution - 0130, Kingswood, New South Wales

Local Institution - 0157, Macquarie University, New South Wales

Local Institution - 0043, St Leonards, New South Wales

Local Institution - 0143, North Adelaide, South Australia

Local Institution - 0037, Heidelberg, Victoria

Local Institution - 0038, Murdoch, Western Australia

Local Institution - 0090, Klagenfurt Am Woerthersee, Not set

Local Institution - 0091, Krems, Not set

Local Institution - 0011, Linz, Not set

Local Institution - 0012, Wien, Not set

Local Institution - 0060, Bruxelles, Not set

Local Institution - 0063, Gent, Not set

Local Institution - 0062, Wilrijk, Not set

Local Institution - 0094, Fortaleza, Ceara

Local Institution - 0099, Ipatinga, Minas Gerais

Local Institution - 0092, Ijui, RIO Grande DO SUL

Local Institution - 0212, Porto Alegre, RIO Grande DO SUL

Local Institution - 0097, Porto Alegre, RIO Grande DO SUL

Local Institution - 0098, Barretos, Sao Paulo

Local Institution - 0095, Jau, Sao Paulo

Local Institution - 0093, Sao Jose Do Rio Preto, Sao Paulo

Local Institution - 0164, Rio De Janeiro, Not set

Local Institution - 0214, Sao Paulo, Not set

Local Institution - 0159, Kelowna, British Columbia

Local Institution - 0182, North York, Ontario

Local Institution - 0192, Chicoutimi, Quebec

Local Institution - 0190, Montreal, Quebec

Local Institution - 0053, Santiago, Metropolitana

Local Institution - 0052, Santiago, Metropolitana

Local Institution - 0210, Santiago, Metropolitana

Local Institution - 0054, Santiago, Metropolitana

Local Institution - 0201, Colombia, Bogota

Local Institution - 0104, Bucaramanga, Not set

Local Institution - 0103, Monteria, Not set

Local Institution - 0148, Helsinki, Not set

Local Institution - 0145, Tampere, Not set

Local Institution - 0146, Turku, Not set

Local Institution - 0202, Brest, Cedex

Local Institution - 0204, Créteil, Val-de-Marne

Local Institution - 0205, Amiens, Not set

Local Institution - 0198, Angers, Not set

Local Institution - 0101, Besancon, Not set

Local Institution - 0217, Bordeaux, Not set

Local Institution - 0199, Clermont-ferrand, Not set

Local Institution - 0206, La Tronche, Not set

Local Institution - 0075, Marseille, Not set

Local Institution - 0200, Montpellier Cedex 5, Not set

Local Institution - 0074, Nice, Not set

Local Institution - 0163, Paris, Not set

Local Institution - 0020, Pierre Benite Cedax, Not set

Local Institution - 0188, Saint Herblain Cedex, Not set

Local Institution - 0002, Strasbourg Cedex, Not set

Local Institution - 0003, TOULOUSE Cedex 9, Not set

Local Institution - 0100, Mainz, Rheinland-Pfalz

Local Institution - 0078, Aachen, Not set

Local Institution - 0015, Erfurt, Not set

Local Institution - 0081, Essen, Not set

Local Institution - 0086, Frankfurt Main, Not set

Local Institution - 0080, Goettingen, Not set

Local Institution - 0013, Herne, Not set

Local Institution - 0010, Jena, Not set

Local Institution - 0084, Luebeck, Not set

Local Institution - 0079, Magdeburg, Not set

Local Institution - 0082, Muenchen, Not set

Local Institution - 0016, Nuernberg, Not set

Local Institution - 0085, Trier, Not set

Local Institution - 0195, Athens, Attikí

Local Institution - 0031, Larissa, Thessalía

Local Institution - 0194, Chaidari, Not set

Local Institution - 0196, Tel Aviv, Tel-Aviv

Local Institution - 0068, Beer Sheva, Not set

Local Institution - 0066, Haifa, Not set

Local Institution - 0067, Ramat Gan, Not set

Local Institution - 0064, Bari, Not set

Local Institution - 0193, Forlì, Not set

Local Institution - 0032, Milano, Not set

Local Institution - 0065, Modena, Not set

Local Institution - 0033, Padova, Not set

Local Institution - 0034, Pisa, Not set

Local Institution - 0035, Roma, Not set

Local Institution - 0186, Komaki, Aichi

Local Institution - 0184, Sapporo, Hokkaido

Local Institution - 0177, Sapporo, Hokkaido

Local Institution - 0185, Sapporo, Hokkaido

Local Institution - 0179, Tsukuba-shi, Ibaraki

Local Institution - 0171, Kita-gun, Kagawa

Local Institution - 0169, Yokohama, Kanagawa

Local Institution - 0168, Niigata-shi, Niigata

Local Institution - 0173, Osakasayama, Osaka

Local Institution - 0175, Takatsuki City, Osaka

Local Institution - 0176, Hidaka-shi, Saitama

Local Institution - 0170, Hamamatasu, Shizuoka

Local Institution - 0178, Minato-ku, Tokyo

Local Institution - 0172, Shinjuku-ku, Tokyo

Local Institution - 0174, Fukuoka, Not set

Local Institution - 0180, Kyoto, Not set

Local Institution - 0137, Goyang-si, Gyeonggi-do

Local Institution - 0203, Seongnam-si, Kyǒnggi-do

Local Institution - 0220, Busan, Not set

Local Institution - 0218, Daegu, Not set

Local Institution - 0208, Gyeongsangnam-do, Not set

Local Institution - 0215, Seongnam-si,, Not set

Local Institution - 0140, Seoul, Not set

Local Institution - 0136, Seoul, Not set

Local Institution - 0211, Seoul, Not set

Local Institution - 0138, Seoul, Not set

Local Institution - 0160, La Paz, BAJA Californa SUR

Local Institution - 0102, Zapopan, Jalisco

Local Institution - 0056, Monterrey, Nuevo LEON

Local Institution - 0105, Colima, Not set

Local Institution - 0070, Amsterdam, Not set

Local Institution - 0072, Groningen, Not set

Local Institution - 0073, Sittard-Geleen, Not set

Local Institution - 0087, Auckland, Not set

Local Institution - 0089, Christchurch, Not set

Local Institution - 0158, Gralum, Not set

Local Institution - 0132, Lorenskog, Not set

Local Institution - 0133, Oslo, Not set

Local Institution - 0153, Lisboa, Not set

Local Institution - 0152, Porto, Not set

Local Institution - 0219, Cluj-Napoca, Not set

Local Institution - 0076, Craiova, Not set

Local Institution - 0058, Sector 2, Not set

Local Institution, Saint-Petersburg, Not set

Local Institution, St Petersburg, Not set

Local Institution - 0154, Singapore, Not set

Local Institution - 0113, Lugo, Not set

Local Institution - 0111, Madrid, Not set

Local Institution - 0112, Madrid, Not set

Local Institution - 0114, Madrid, Not set

Local Institution - 0156, Malaga, Not set

Local Institution - 0109, Sevilla, Not set

Local Institution - 0135, Kaohsiung, Not set

Local Institution - 0165, Taichung, Not set

Local Institution - 0141, Taipei City, Not set

Local Institution - 0139, Taipei, Not set

Local Institution - 0128, Chelmsford, Essex

Local Institution - 0127, York, Yorkshire

Local Institution - 0122, Glasgow, Not set

Local Institution - 0117, Lancaster, Not set

Local Institution - 0121, London, Not set

Local Institution - 0124, Oxford, Not set

Conditions: Muscle-Invasive Bladder Cancer, Urinary Bladder Neoplasms

Learn More ›

Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

NCT03345784

Terminated

This phase I trial studies the side effects and best dose of adavosertib when given together with external beam radiation therapy and cisplatin in treating patients with cervical, vaginal, or uterine cancer. Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. External beam radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tu... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

01/25/2024

Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California +7 locations

Conditions: Endometrioid Adenocarcinoma, Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma, Stage I Uterine Corpus Cancer AJCC v7, Stage I Vaginal Cancer AJCC v6 and v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Cervical Cancer AJCC v6 and v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7, Stage III Uterine Corpus Cancer AJCC v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIA Cervical Cancer AJCC v6 and v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Cervical Carcinoma, Vaginal Carcinoma

Learn More ›

A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer

NCT01693718

Completed

The goal of the study is to test a particular combination of drugs and determine their ability to completely eliminate head and neck cancer.

Gender:

ALL

Ages:

59 years and above

Trial Updated:

01/25/2024

Locations: The University of Chicago, Chicago, Illinois

Conditions: Head and Neck

Learn More ›

Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer

NCT01588431

Completed

Locally advanced squamous cell carcinoma of the head and neck (SCCHN) is treated with various combinations of radiation and chemotherapy. This study aims to evaluate the rate of complete responses with induction therapy (primary endpoint) and progression-free survival, overall survival and objective response rates of docetaxel, cisplatin, cetuximab, and bevacizumab (TPE-A) followed by radiation therapy, cisplatin, cetuximab, and bevacizumab (XPE-A). Also, the investigators plan to investigate a... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/18/2024

Locations: Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas

Conditions: Carcinoma, Squamous Cell of Head and Neck

Learn More ›

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

NCT03840902

Terminated

The main purpose of this study was to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/12/2024

Locations: University of California Irvine Medical Center, Orange, California +103 locations

University of California Irvine Medical Center, Orange, California

UCLA Hematology Oncology - Main Site - 2020 Santa Monica, Santa Monica, California

University of Colorado Health - Memorial Hospital - Memorial Hospital, Colorado Springs, Colorado

Hematology Oncology Associates, Fort Collins, Colorado

Lynn Cancer Institute Center, Boca Raton, Florida

Holy Cross Hospital - Michael and Dianne Bienes CCC, Fort Lauderdale, Florida

Sylvester Comprehensive Cancer Center - University of Miami Health System, Miami, Florida

The University of Chicago Medical Center, Chicago, Illinois

American Health Network of Indiana, LLC, Indianapolis, Indiana

Franciscan St. Francis Health Cancer Center, Indianapolis, Indiana

Baptist Health Lexington Oncology Associates, Lexington, Kentucky

University of Maryland - DUPLICATE/Pediatric Surgery, Baltimore, Maryland

Henry Ford Health System, Detroit, Michigan

Mayo Clinic, Rochester, Minnesota

Columbia University Medical Center, New York, New York

Hematology Oncology Center of Nyack Hospital, Nyack, New York

FirstHealth of the Carolinas, Inc., Pinehurst, North Carolina

The James Cancer Hospital and Solove Research Institute, Columbus, Ohio

UPMC Cancer Center, Pittsburgh, Pennsylvania

Vanderbilt University Medical Center, Nashville, Tennessee

University of Texas MD Anderson Cancer Center - Unit 432 Thoracic Head and Neck Medical Oncology, Houston, Texas

Sanatorio Allende, Cordoba, Not set

Centro Polivalente de Asistencia e Inv. Clinica CER, San Juan, Not set

Bendigo Hospital, Bendigo, Not set

The Townsville Hospital, Douglas, Not set

Calvary Central Districts Hospital, Elizabeth Vale, Not set

St Vincent's Hospital Melbourne - PARENT, Fitzroy, Not set

University Hospital Geelong - PARENT, Geelong, Not set

Austin Health, Heidelberg Heights, Not set

Centro de Investigacion Pergamino SA, Pergamino, Not set

Prince of Wales Hospital, Randwick, Not set

Sunshine Hospital, St Albans, Not set

Royal North Shore Hospital, St Leonards, Not set

South West Healthcare - South West Oncology, Warrnambool, Not set

UZ Leuven, Leuven, Not set

Clinique et Maternite St Elisabeth Namur, Namur, Not set

AZ Delta, Roeselare, Not set

CHU Mont-Godinne, Yvoir, Not set

Hospital de Câncer de Barretos - Fundação Pio XII, Barretos, Not set

Clínica de Neoplasias Litoral Ltda., Itajaí, Not set

HGB - Hospital Giovanni Battista - Mãe de Deus Center - Centro de Pesquisa Clínica - Instituto do Câncer, Porto Alegre, Not set

Hospital São Lucas da PUCRS, Porto Alegre, Not set

COI - Clínicas Oncológicas Integradas, Rio de Janeiro, Not set

A. C. Camargo Cancer Center - Fundação Antônio Prudente, São Paulo, Not set

ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira, São Paulo, Not set

BC Cancer Agency Center for the Southern Interior, Kelowna, Not set

Peking University Cancer Hospital, Beijing, Not set

Jilin Cancer Hospital - Oncology, Changchun, Not set

Hangzhou First People's Hospital, Hangzhou, Not set

Fakultni nemocnice Olomouc - Dept of Onkologicka klinika, Olomouc, Not set

Centre Hospitalier de la Côte Basque - Service de Pneumologie, Bayonne, Not set

Hôpital Nord - AP-HM Marseille# - Service d'Oncologie Multidisciplinaire, Marseille cedex 20, Not set

Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris - Service d'Oncologie Médicale, Paris Cedex 05, Not set

CHU Nantes - Hôpital Guillaume et René Laënnec - Service de Pneumologie, Saint Herblain, Not set

Asklepios Klinik Harburg - Medizinische Abteilung I, Hamburg, Not set

Pius-Hospital Oldenburg - Klinik f. Haematologie und Onkologie, Oldenburg, Not set

Nippon Medical School Hospital - Dept of Respiratory Medicine, Bunkyo-ku, Not set

Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital - Dept of Respiratory Medicine, Bunkyo-ku, Not set

Saitama Medical University International Medical Center - Dept of Respiratory Medicine, Hidaka-shi, Not set

National Cancer Center Hospital East - Dept of Respiratory Medicine, Kashiwa-shi, Not set

Kobe City Hospital Organization Kobe City Medical Center General Hospital - Dept of Respiratory Medicine, Kobe-shi, Not set

Cancer Institute Hospital of JFCR - Dept of Respiratory Medicine, Koto-ku, Not set

Kurume University Hospital - Dept of Lung Cancer Center, Kurume-shi, Not set

Aichi Cancer Center Hospital - Dept of Respiratory Medicine, Nagoya-shi, Not set

Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka-shi, Not set

Kindai University Hospital (13859), Osakasayama-shi, Not set

Shizuoka Cancer Center, Sunto-gun, Not set

Kanagawa Cancer Center - Dept of Respiratory Medicine, Yokohama-shi, Not set

Keimyung University Dongsan Hospital, Daegu, Not set

Seoul National University Bundang Hospital, Seongnam, Not set

Asan Medical Center, Seoul, Not set

Korea University Anam Hospital, Seoul, Not set

Severance Hospital, Yonsei University, Seoul, Not set

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Not set

Jeroen Bosch Ziekenhuis, 's Hertogenbosch, Not set

Meander Medisch Centrum - Dep of Pulmonology, Amersfoort, Not set

Amphia Ziekenhuis - PARENT - Parent, Breda, Not set

Martini ziekenhuis, Groningen, Not set

Ziekenhuis St. Jansdal, Harderwijk, Not set

St. Antonius Ziekenhuis - Dept Pulmonology - Nieuwegein, Nieuwegein, Not set

St. Elisabeth Ziekenhuis - Parent, Tilburg, Not set

ISALA Klinieken Locatie Sophia, Zwolle, Not set

Hospital del Mar - Servicio de Oncologia, Barcelona, Not set

Hospital Universitari Quiron Dexeus - Servicio de Oncologia Medica, Barcelona, Not set

Hospital Universitari Vall d'Hebron - Dept of Oncology, Barcelona, Not set

ICO l´Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia, L'Hospitalet de Llobregat, Not set

Clinica Universidad de Navarra (MAD) - Oncology Service, Madrid, Not set

Hospital Universitario 12 de Octubre - Servicio de Oncologia, Madrid, Not set

Hospital Universitario Clinico San Carlos - Servicio de Oncologia, Madrid, Not set

Hospital Universitario HM Madrid Sanchinarro - Servicio de Oncologia, Madrid, Not set

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Not set

Hospital Regional Universitario de Malaga, Málaga, Not set

Clinica Universidad de Navarra, Pamplona, Not set

Complejo Hospitalario Universitario de Santiago - Servicio de Oncologia Medica, Santiago de Compostela, Not set

Hospital Universitario Nuestra Señora de Valme - Servicio de Oncologia, Sevilla, Not set

Hospital Universitario Virgen del Rocio - Servicio de Oncologia, Sevilla, Not set

Hospital Universitario Virgen Macarena - Servicio de Oncologia, Sevilla, Not set

Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica, Valencia, Not set

Hospital Universitari i Politecnic La Fe - Servicio de Oncologia Medica, Valencia, Not set

Hospital Alvaro Cunqueiro - Servicio de Oncologia, Vigo, Not set

Taichung Veterans General Hospital, Taichung, Not set

Chi Mei Medical Center, Liou Ying, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Tri-Service General Hospital, Taipei, Not set

Conditions: Non-small Cell Lung Cancer

Learn More ›

Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

NCT00085202

Completed

Drugs used in chemotherapy, such as vincristine, cisplatin, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. Autologous stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy. It is not yet known which radiation therapy regimen combined... Read More

Gender:

ALL

Ages:

Between 3 years and 21 years

Trial Updated:

01/11/2024

Locations: Duke Comprehensive Cancer Center, Durham, North Carolina +8 locations

Conditions: Brain and Central Nervous System Tumors

Learn More ›

Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A

NCT01858922

Completed

Subjects have a type of cancer called Hodgkin Disease (HD), a cancer of the lymph system. The lymph system is made up of tissue throughout the body that makes and stores infection-fighting cells. HD is one of the most treatable childhood cancers. The standard treatment for HD involves chemotherapy (treatment with anti-cancer drugs) and radiation therapy (the use of high-dose x-rays to get rid of cancer cells). Although they are cured from their cancer, some patients experience negative side effe... Read More

Gender:

ALL

Ages:

All

Trial Updated:

01/10/2024

Locations: Texas Children's Hospital, Houston, Texas

Conditions: Hodgkin Disease

Learn More ›

Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)

NCT01437449

Completed

Docetaxel and cetuximab are FDA-approved for the treatment of squamous cell carcinoma of the head and neck (SCCHN). Cisplatin and carboplatin, while not FDA-approved for SCCHN, have been used as standard of care in SCCHN patients in combination with other drugs. This study evaluates if weekly cisplatin and docetaxel, in combination with cetuximab, is effective in palliative treatment of patients with SCCHN. These drugs will be given intravenously weekly, repeated 3 of every 4 weeks until evidenc... Read More

Gender:

ALL

Ages:

16 years and above

Trial Updated:

01/07/2024

Locations: University of California Davis Medical Center, Davis, California +1 locations

Conditions: Head and Neck Cancer

Learn More ›

Drug Screening Using IMD in Bladder Cancer

NCT06204614

Not Yet Recruiting

This research study involves implanting up to 4 microdevices, each small enough to fit inside the tip of a needle, into a tumor. These devices will release microdoses (many thousands of times less than a treatment dose) of different cancer drugs into the tumor. After approximately 72 hours, the devices and small regions of surrounding tissue will be removed and studied. There will be a follow-up visit within 42 days of device removal to assess for potential safety issues or side effects.

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

01/03/2024

Locations: Brigham and Women's Hospital, Boston, Massachusetts

Conditions: Muscle Invasive Bladder Urothelial Carcinoma

Learn More ›

Browse by State

Cisplatin treatment options in Alabama

Cisplatin treatment options in Alaska

Cisplatin treatment options in Arizona

Cisplatin treatment options in Arkansas

Cisplatin treatment options in California

Cisplatin treatment options in Colorado

Cisplatin treatment options in Connecticut

Cisplatin treatment options in Delaware

Cisplatin treatment options in District of Columbia

Cisplatin treatment options in Florida

Cisplatin treatment options in Georgia

Cisplatin treatment options in Hawaii

Cisplatin treatment options in Idaho

Cisplatin treatment options in Illinois

Cisplatin treatment options in Indiana

Cisplatin treatment options in Iowa

Cisplatin treatment options in Kansas

Cisplatin treatment options in Kentucky

Cisplatin treatment options in Louisiana

Cisplatin treatment options in Maine

Cisplatin treatment options in Montana

Cisplatin treatment options in Nebraska

Cisplatin treatment options in Nevada

Cisplatin treatment options in New Hampshire

Cisplatin treatment options in New Jersey

Cisplatin treatment options in New Mexico

Cisplatin treatment options in New York

Cisplatin treatment options in North Carolina

Cisplatin treatment options in North Dakota

Cisplatin treatment options in Ohio

Cisplatin treatment options in Oklahoma

Cisplatin treatment options in Oregon

Cisplatin treatment options in Maryland

Cisplatin treatment options in Massachusetts

Cisplatin treatment options in Michigan

Cisplatin treatment options in Minnesota

Cisplatin treatment options in Mississippi

Cisplatin treatment options in Missouri

Cisplatin treatment options in Pennsylvania

Cisplatin treatment options in Rhode Island

Cisplatin treatment options in South Carolina

Cisplatin treatment options in South Dakota

Cisplatin treatment options in Tennessee

Cisplatin treatment options in Texas

Cisplatin treatment options in Utah

Cisplatin treatment options in Vermont

Cisplatin treatment options in Virginia

Cisplatin treatment options in Washington

Cisplatin treatment options in West Virginia

Cisplatin treatment options in Wisconsin

Cisplatin treatment options in Wyoming